Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

Xuemei Cao1,2†‡, Min Mao2,3‡, Junlin Diao1,2‡, Yi Hou2,4, Hong Su2,3, Yongjun Gan4, Jibin Li5, Xiaoyong Tong6, Chaodong Wu7, Zhong Zuo3* and Xiaoqiu Xiao1,2*

1Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 2The Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 3Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 4Experimental Teaching & Management Center, Chongqing Medical University, Chongqing, China, 5Department of Nutrition and Food Hygiene, School of Public Health and Management, Chongqing Medical University, Chongqing, China, 6School of Pharmaceutical Sciences, Chongqing University, Chongqing, China, 7Department of Nutrition and Food Science, Texas A&M University, College Station, TX, United States

The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor γ (PPARγ). PPARγ partial agonists showed superior pharmacological profiles to rosiglitazone. This study compared differences in cardiac morphology and function of the PPARγ partial agonist CMHX008 with rosiglitazone. High-fat diet (HFD) induced obese mice, ob/ob mice and cardiomyocytes overexpressing PPARγ2 were treated with CMHX008 or rosiglitazone. Heart function, myocardial morphology, and hypertrophy-related gene expression were examined. Clinical information from patients with type 2 diabetes mellitus (T2DM) who had taken rosiglitazone and undergone Doppler echocardiography was collected. HFD and ob/ob mice significantly developed cardiac contractile dysfunction, with upregulated PPARγ2 protein levels in heart tissues. Cardiomyocytes of HFD and ob/ob mice were disorderly arranged, the cell areas expanded, and collagen accumulated. In vitro cardiomyocytes overexpressing PPARγ2 displayed obvious structural abnormalities and high mRNA levels of ANP and BNP, critical hypertrophy-related genes. HFD-fed mice treated with rosiglitazone or CMHX008 had significantly improved cardiac function, but rosiglitazone induced higher expression of ANP and βMHC and hypertrophic cardiomyopathy, while CMHX008 did not. Patients with T2DM taking rosiglitazone exhibited increased thickness of the posterior wall and the ventricular septum, suggesting cardiac hypertrophy. Our findings show that diabetic cardiomyopathy was associated with ectopic overexpression of PPARγ2. The full agonist rosiglitazone prevents cardiac dysfunction at the expense of compensatory
accumulating evidence has suggested that novel PPAR γ agonists that do not fully stimulate PPAR γ with lower damage to metabolic organs (Wang et al., 2014; Kolli et al., 2014; Yasmin et al., 2017). Studies have also shown that the CKD-501 compound has better safety in the heart tissue, and mice showed hypertrophic cardiomyopathy (Son et al., 2007). However, the mechanism underlying the effect of PPARγ2 on heart function remains to be elucidated. For this reason, we focused on examining whether PPARγ2, the regulator of fatty acid-related factors, was a contributor to diabetic cardiomyopathy.

INTRODUCTION

Diabetes as a chronic, metabolic disease has recently attracted widespread attention. As WHO showed, type 2 diabetes mellitus (T2DM) is believed to account for approximately 90% of all cases of diabetes, which is caused by insulin resistance or insufficient insulin. Obesity-induced insulin resistance is associated with T2DM (Saltiel, 2006; Malone and Hansen, 2019). Thiazolidinediones (TZDs) as insulin sensitizers are important hypoglycemic agents for T2DM (Eldor et al., 2013; Nanjan et al., 2018). TZDs, including rosiglitazone and pioglitazone, are synthetic full agonists of peroxisome proliferators activated receptor γ (PPARγ), and can activate PPARγ to better combine with insulin receptors for maintaining glucose levels and increasing adiponectin expression in patients with diabetes (Yki-Järvinen, 2004; Rizos et al., 2016). However, activating PPARγ by full agonists is accompanied by some side effects, most remarkably, congestive heart failure caused by rosiglitazone (Home et al., 2009; MacDonald et al., 2011). Although careful safety evaluations demonstrated that rosiglitazone was with no increased risk of heart attack compared to the standard T2DM medicines metformin and sulfonylurea, great concerns remained as to the potential side effects of classical TZDs (Consoli and Formoso, 2013; Hiatt et al., 2013; Goltsman et al., 2016). In order to reduce these side effects, such as heart problems, bone loss, weight gain, and fluid retention (Komajda et al., 2010; Lecka-Czernik, 2010; Ahmadian et al., 2013; Stechschulte et al., 2016; Lebovitz, 2019), several strategies have been examined and accumulating evidence has suggested that novel PPARγ agonists that do not fully stimulate PPARγ can also play an important role in enhancing insulin sensitivity (Ryan et al., 2011; Kolli et al., 2014; Yasmin et al., 2017). Studies have also demonstrated that partial agonists retain insulin sensitization with lower damage to metabolic organs (Wang et al., 2014; Chigurupati et al., 2015). A novel PPARγ partial agonist, SPPARyM5, increased insulin sensitization and reduced the cardiovascular side effects (Chang et al., 2008). Another study showed that the CKD-501 compound has better safety in the cardiotoxicity of db/db mice than full PPARγ agonists (Yang et al., 2013). Thus, it is postulated that PPARγ partial agonists can be developed into a more ideal antiabetic agent. In this study, the structure of TZDs was modified to synthesize a novel compound, namely, CMHX008, which has been identified to have a lower PPARγ agonist activity, promote preadipocyte differentiation, and improve insulin sensitivity, with minor influence on weight gain and bone loss compared with rosiglitazone (Ming et al., 2014; Hou et al., 2018). These findings revealed CMHX008 as a new PPARγ partial agonist; thus, it was expected to have a similar efficacy in increasing glucose uptake and potential effects on the risk of cardiovascular events as rosiglitazone. Therefore, we will further explore the underlying mechanism of cardiac hypertrophy after treatment with CMHX008 and rosiglitazone.

MATERIALS AND METHODS

Animals and Treatment

Six-week-old male C57BL/6 mice were purchased from the Experimental Animal Center of Chongqing Medical University. Mice were randomly divided into two groups, and each group was fed a control low-fat diet (LFD, with 10% of calories from fat, D12450B; Research Diet) or a high-fat diet (HFD, 60% of calories from fat, D12492; Research Diet) for 12 weeks in SPF conditions. Mice on HFD feeding did not reach the criteria for diet induced obesity (Enriori et al., 2007) were eliminated from the following studies. Beginning with 13-weeks on HFD, obese mice were randomly divided into five groups and switched to gavage daily with vehicle (HFD-Veh) or rosiglitazone (3 or 10 mg kg⁻¹; HFD-R3 or HFD-R10) or CMHX008 (3 or 10 mg kg⁻¹; HFD-C3, or HFD-C10), respectively. Ob/ob mice were generated by our lab. All mice were kept in temperature- (25°C) and humidity (60%)-controlled rooms on a 12/12-h light/dark cycle. The mice were weighed weekly to monitor their body weight.

Color Doppler Ultrasonography Assay

The mice were subjected to abdominal hair removal treatment using a depilatory cream, anesthetized with isoflurane, and a ventilator (Harvard, United States) was used to maintain a stable heart rate. Color Doppler ultrasonography (Vivid 7 Dimension)
was used to obtain the data from two-dimensional ultrasound. M-type ultrasonographic parameters are as follows: 1. left ventricular end-diastolic posterior wall thickness (LVPWd) and end-systolic posterior wall thickness (LVPWs); 2. left ventricular end-diastolic septal thickness (IVSd) and end-systolic septal thickness (IVSs); 3. left ventricular end-diastolic diameter (LVIDd) and end-systolic diameter (LVIDs) × 100%; 4. left ventricular fractional shortening (FS)= (LVIDd - LVIDs)/ LVIDd × 100%; 5. ejection fraction (EF) = SV/LVEDV × 100%; and 6. mitral valve flow rate = E/A.

**Automatic Biochemistry Analyzer Assay**
After administration of ether anesthesia, we obtained blood samples from mice with the RIA kit (Megran 1.0; OriGene, United States) and DNA were made of 100 μl containing 10% FBS for 24 h. Complexes of transfection reagent (10 μl of transfection reagent, mixed, and 100 μl of DNA, a n d 3 μl of rosiglitazone or CMHX008 for 24 h. We observed cells using an incubator for 24 h. Subsequently, the cells were centrifuged for 3 min at a speed of 800 rpm, plated at 5 × 104 cells per well in 24-well plates, and incubated in DMEM medium (DMEM containing 4.5 g/L glucose; PAN Biotech, French) supplemented with 10% fetal bovine serum (FBS; PAN Biotech, Germany) and 1% Penicillin-Streptomycin Solution (Beyotime, China) maintained at 37°C in an atmosphere of 95% air and 5% CO2. Cells were digested with 1 ml of trypsin (HyClone, United States) at 37°C for 1–2 min. After digesting, cells were centrifuged for 3 min at a speed of 800 rpm, plated at 5 × 104 cells per well in 24-well plates, and incubated in DMEM containing 10% FBS for 24 h. Complexes of transfection reagent (Megran 1.0; OriGene, United States) and DNA were made of 100 μl of DMEM, 1 μg of DNA, and 3 μl of transfection reagent, mixed, and incubated at room temperature for 10 min. Complexes (1 μg/ml) were added in 24 wells and incubated for 24 h to detect target mRNA and protein by RT-PCR and western blot. After successful transfection, the cells transfected with PCMV6-PPARγ2 (OriGene, United States) were treated with 10 μmol/ml rosiglitazone or CMHX008 for 24 h.

**Quantitative Real-Time PCR**
Heart tissues were stored in RNAstore Reagent (#Q5324, TIANGEN). Total RNA was extracted from heart tissues or cardiac myocytes using TRIzol reagent (Invitrogen, United States) according to the manufacturer’s instructions. cDNA was synthesized with the PrimeScript™ RT Reagent Kit (TAKARA, Japan). RT-PCR was carried out using the SYBR Green premix Ex Taq™ Kit (Roche, Germany). Expression of PPARγ2, BNP, and β-MHC mRNA in heart tissues and BNP and ANP mRNA in cardiomyocytes was measured using RT-PCR. After the reaction system was completed, all gene levels were analyzed according to the Cq values. Primer sequences were as described in Table 1. The protocol of PCR was as follows: 95.0°C for 0.5 min, 95.0°C for 5 s, 60°C for 34 s, more than 39 cycles of 95.0°C for 5 s, with additional melt curve program included (Thornton and Basu, 2015).

**Western Blotting**
We stored heart tissues at −80°C. Proteins from tissues or cells were isolated and extracted using RIPA Buffer (89,900, Roche, Germany) with protease inhibitor (Roche, Germany). A BCA protein assay kit (P0010, Beyotime, China) was used to detect the protein concentration. Protein samples were separated in 8% sodium dodecyl sulfate polyacrylamide gels and transferred onto polyvinylidene fluoride membranes (Millipore, United States). Membranes were blocked with skimmed milk powder (Bio-Rad, United States) for 1.5 h and incubated at 4°C overnight with primary antibodies against PPARγ2 (1:1,000, ab45036, Abcam), DDK (1:2,000, TA50011, OriGene), and GAPDH (1:500, TA50545, ZSGB-Bio). Then, the membranes were washed in TBST 3 times, followed by incubation in secondary antibody (horseradish peroxidase-labeled IgG anti-goat/rabbit antibody; 1:2,000, OriGene, China) for 1 h at room temperature. After washing membranes in TBST 3 times, the western blotting detection kit (Millipore, United States) was used for exposure. Densitometric measurements of the bands were performed using FusionCapt Advance software (VILBER, French).

**Immunofluorescence Staining**
The films were plated into 24-well plates and cultured with 5 × 104 cells per well in an incubator for 24 h. Subsequently, the cells were treated with plasmids and drugs for 48 h. Cells were fixed with 4% paraformaldehyde for 20 min and permeabilized with 0.1% Triton-X-100 at room temperature for 15 min. After blocking with 5% bovine serum albumin (GENView, United States) for 1 h, the cells were incubated with primary antibodies against α-SMA (1:100, Santa Cruz) 50 μl at 4°C overnight. Subsequently, cell nuclei were stained with DAPI for 1 min. We observed cells using fluorescence microscopy (Olympus AX70, Japan). The entire experimental process was carried out in the dark.

**Clinical Data Analysis**
To test whether rosiglitazone treatment would cause cardiac hypertrophy, we collected the information of patients with T2DM from the Medical Reports Department of the First Affiliated Hospital of Chongqing Medical University in the recent three years (from 2017.01.01 to 2019.12.31). At first, we selected the patients with the examination of heart color doppler ultrasound and heart function. Then patients taking
Rosiglitazone as one of the combinational therapy were selected and the plasma biochemical index and color Doppler ultrasonography data were collected. Another group of age, sex, and disease course matched patients without taking rosiglitazone was used as a control to compare the differences in cardiac structure and function, such as ventricular wall thickness, ventricular septal thickness, ejection fraction, mitral valve flow rate, and etc.

| Gene name | Sequence 5'-3' (forward) | Sequence 5'-3' (reverse) |
|-----------|--------------------------|--------------------------|
| GAPDH     | GACATCAAGAAGGGAAGC       | GAAGGTGAAGAAGGGAAGT      |
| ANF       | TTAGGAGACTGGCAGGACAA     | GAAGAAGCAGGAGGGAAT       |
| BNP       | AGGAAATGCCCCAGACAGC      | TGGTGGAAACAGCAAGCTTGA    |
| β-MHC     | CCGAGTCAGGCAAGTACCA      | CTTCAOCGGGACCCCTTGA      |
| PPARγ2    | GACGCTGGCATGCTTT         | CCAGAGACTGGGAGCTCA       |

**TABLE 1 | Primer information of quantitative real-time PCR experiments.**

**FIGURE 1 | Obesity was associated with cardiac dysfunction and ectopically upregulated PPARγ2 expression in the heart.** (A) The ratio of the heart weight to tibia length. (B) and (C) The representative 2D echocardiograph and M-mode image of lean and obese mice. (D) Quantification of ejection fraction (EF) and fractional shortening (FS). (E) Measurements of the left ventricle wall thickness in systole (LVPWs) and diastole (LVPWd). (F) The left ventricle internal diameters in systole (LVIDs) and diastole (LVIDd). (G) Representative PPARγ2 bands of Western blot in heart tissues. (H) Quantified protein levels of PPARγ2 in the heart of the LFD group or obese mice. Mean ± SEM, n = 5–8 mice per group, *p < 0.05, **p < 0.01 vs. LFD.
Statistical Analysis
We use SPSS18 software to analyze all data. Data values are presented as the mean ± SEM. Comparisons of two groups were made using the LSD test and one-way ANOVA. Statistical significance was expressed as *p < 0.05, **p < 0.01, and ***p < 0.001.

RESULTS

Obesity Was Associated With Cardiac Dysfunction and Ectopically Upregulated PPARγ2 Expression in the Heart

Obesity is a major risk factor for diabetes and cardiovascular diseases. The expression of PPARγ2 in heart tissues was evaluated in two models of obesity using C57BL/6 mice fed HFD for 12 weeks and genetic ob/ob mice. The ratio of the heart weight to tibia length was used as an indicator of cardiac size. The ratios in the HFD and ob/ob mice were significantly higher than those in the LFD mice (Figure 1A). Electron microscopy results showed that the mitochondria were swelled, cristae were ruptured, and endoplasmic reticulum was extended in the myocardium of HFD and ob/ob mice. In addition, muscle fibers were partially dissolved in the myocardium of ob/ob mice (Figure 1B). Compared with the LFD group, cardiac color Doppler ultrasonography showed that EF and FS decreased in the HFD and ob/ob groups, which indicated a decrease in contractility. Enlargement of the left ventricular diameter was also observed in the HFD group (Figures 1C–F). Although PPARγ2 regulates metabolic-related genes and is primarily expressed in adipocytes, we found that it was also expressed in myocardium. Compared with the LFD control, the HFD and ob/ob mice showed approximately a 1-fold and 4-fold increase at the PPARγ2 protein levels (Figures 1G,H). Thus, we believe that PPARγ2 is highly expressed in the heart of HFD mice and ob/ob mice.
Overexpression of PPARγ2 in Cardiomyocytes is Sufficient to Lead to Hypertrophy

To investigate the potential role of PPARγ2 overexpression in cardiomyocytes, we transfected Myc-DDK-tagged PCMV6 and PCMV6-PPARγ2 plasmids into mouse cardiac myocytes (MCM) cells and detected the levels of PPARγ2 mRNA and protein 24 h after transfection. Results from RT-PCR and Western blotting showed that plasmids were effectively transfected (Figures 2A, B). Compared with the control (CON) group, PCMV6-PPARγ2-transfected cells showed increased BNP mRNA expression (Figure 2C). Consistent with the effects of BNP mRNA expression, the areas of cardiac myocytes were increased after labeling with α-SMA (Figures 2D, E). These results suggest that the areas and heart failure marker gene BNP were increased after overexpression of PPARγ2 in cardiac myocytes, and this should also be evidence that obesity-mediated cardiac hypertrophy and injury may be closely associated with PPARγ2 expression in the myocardium.

Rosiglitazone and CMHX008 Displayed Different Effect on Cardiac Weight and Structure

Rosiglitazone and CMHX008 Ameliorate HFD-Induced Myocardial Function but Have Different Effects on Echocardiographical Indexes

We then evaluated whether rosiglitazone and CMHX008 treatment could improve HFD feeding induced myocardial dysfunction by echocardiography (Figures 4A, B). Compared with vehicle-treated HFD mice (H-V), treatment with 10 mg/kg of rosiglitazone (H-R10) or CMHX008 (H-C10) significantly improved the ejection fraction (EF) and fractional...
shortening (FS), which were close to those of the vehicle-treated LFD control mice (L-V) (Figures 4C,D). In addition, the peak early (E) and late (A) mitral inflow velocities were measured and E/A ratio was calculated. As shown in Figure 4E, E/A showed no significant change among all groups of mice. H-R10 and H-C10 mice showed significantly decreased end-systolic diameter (LVIDs) and the left ventricle end-diastolic diameter (LVIDd) was also reduced in H-C10 group compared with H-V mice (Figure 4F). Echocardiography showed that the left ventricular end-systolic posterior wall thickness (LVPWs) was significantly thickened in the H-R10 group compared with that in the H-V mice, while the H-C10 group had a tendency of attenuating the thickening of LVPWs compared with the H-V group (Figure 4G). The left ventricular end-systolic septal thickness (IVSs) and end-diastolic septal thickness (IVSd) of the H-R10 group also showed a significant thickening, while increased IVSs was not presented in the H-C10 group (Figure 4H). Taken together, we identified that the H-R10 mice had a tendency toward cardiac hypertrophy, especially in the left ventricle posterior wall thickness and left ventricle septal thickness; however, the ejection fraction (EF) ratio and fractional shortening (FS) had not been damaged and increased reflexively. LVPW increased and EF changed slightly in the H-R10 group, which suggested that these mice were in the middle stage of diabetic cardiomyopathy and that cardiac ejection function was not damaged during this period.

**Cardiomyocyte Changes Following Treatment With CMHX008 and Rosiglitazone**

To further investigate the effect of rosiglitazone and CMHX008 on cardiomyocytes, we treated PPARγ2 overexpressed cardiomyocytes with rosiglitazone and CMHX008 and observed that rosiglitazone further aggravated hypertrophic appearance of cardiomyocytes through staining for α-SMA while CMHX008 had no obvious changes (Figure 5A). In addition, BNP and ANP, the heart failure marker genes, were highly expressed in cells treated with rosiglitazone, and the levels were higher than those in cells overexpressing PPARγ2, and cells treated with CMHX008 showed no significant difference compared with the normal group (Figures 5B,C). The results showed that rosiglitazone could aggravate the hypertrophy of cardiomyocytes induced by overexpression of PPARγ2, and CMHX008 could improve cell hypertrophy.

**The Effect of Rosiglitazone and CMHX008 on Heart Tissue of C57BL/6 Mice**

From WGA staining (Figures 6A,B), we observed that the cell areas were increased in the H-R10 group compared with those in the H-V group, and the cell hypertrophy in the H-C10 group was attenuated compared with the H-R10 group. In addition, the levels of heart failure-related genes, such as ANP and βMHC, were higher in the H-R10 group than the levels in the H-V group, and CMHX008 treatment reduced the expression of related gene markers compared with rosiglitazone treatment (Figures 6C–E). These results suggest that rosiglitazone may induce obvious cardiomyocyte hypertrophy and while CMHX008 treatment does not have obvious effect on cardiomyocytes.

**Patients Treated With Rosiglitazone had a High Risk of Ventricular Septal Thickness and Posterior Wall Thickness**

We screened 30 patients with type 2 diabetes mellitus who had taken rosiglitazone (+ROSI) group and compared them with 90 patients as the control group with matchable age, sex and disease course but without rosiglitazone treatment (-ROSI group). Table 3 compared the data of the physical and serum biochemical characteristics. The majority of these indexes were comparable except for a modest lower ALP activity and a higher serum creatinine (Scr) level in +ROSI group. However, compared with patients without taking rosiglitazone (-ROSI), patients with rosiglitazone significantly increased, interventricular septal thickness (IVS), left ventricular posterior wall thickness (LVPW) and left atrial diameter (LAD), while left ventricular end diastolic diameter (LVIDdd), ejection fraction (EF) and left ventricular shortening fraction (FS) were not significantly changed, suggesting that patients with rosiglitazone had early myocardial damage and increased early volume load (Table 4).

**DISCUSSION**

The PPAR mediated transcriptional activation includes the initial activation of PPARs by ligand binding at the AF-2 region, heterodimerization with RXR, heterodimers binding to the DNA response element (PPRE), and nuclear receptor coactivator synergistic interaction with PPAR-RXR in the AF-1 region (Ma et al., 2018; Brikto and Dvorak, 2020). Several coactivators, such as CBP/p300, SRC-1, TRAP220, PGC-1α,
RAP250, and cosuppressors, including NcoR and SMRT, coregulate the activity of nuclear receptors and then regulate the activity of transcription-related genes. Upon the activation of PPAR\(\gamma\) partial agonists, the interaction of the coactivators CBP/p300 and SRC-1 with the receptor is weaker than that of PPAR\(\gamma\) full agonists. The activation of histone acetylase by coactivators plays an important role in the regulation of different physiological responses, for example, PGC-1a plays a role in the activation of hyperglycemia, insulin resistance, and cardiomyopathy-related complexes, and transcriptional regulation of mRNA, CBP and SRC mainly regulate glucose and lipid metabolism. By TR-FRET analysis, it was confirmed that the PPAR\(\gamma\) partial agonist F12016 had a lower recruiting ability to coactivators than the PPAR\(\gamma\) complete agonist and reduced the side effect of bone loss (Liu et al., 2021).

**FIGURE 4** Rosiglitazone and CMHX008 ameliorate HFD-induced myocardial function but have different effects on echocardiographical indexes. (A) Representative 2D echocardiograph and, (B) M-mode image of mice treated with CMHX008, rosiglitazone or vehicle; (C) Quantification of ejection fraction (EF), (D) fractional shortening (FS), and (E) the ratio of E to A velocity (E/A); (F) Measurements of the left ventricle internal diameters in systole (LVIDs) and diastole (LVIDd), (G) left ventricle wall thickness in systole (LVPWs) and diastole (LVPWd), and (H) the interventricular septal thickness in systole (IVSs) and diastole (IVSd). Means ± SEM, n = 4–6 mice per group, *p < 0.05 vs. L-V, #p < 0.05 vs. H-V.
FIGURE 5 | Cardiomyocyte changes following treatment with CMHX008 and rosiglitazone in vitro. (A) Representative images of α-SMA staining with CY3 (red) in cardiomyocytes; Measurement of the mRNA levels of the hypertrophic marker genes BNP (B) and ANP (C) in cardiomyocytes. Means ± SEM, from five independent experiments, *p < 0.05 vs. PPARγ2 (−); #p < 0.05 vs. PPARγ2 (+).

FIGURE 6 | Cardiomyocyte changes in HFD mice following treatment with CMHX008 and rosiglitazone. (A) Representative WGA staining in the heart from HFD mice following treatment with CMHX008 and rosiglitazone; (B) Quantified cardiomyocyte size; Measurement of the mRNA levels of the hypertrophic marker genes BNP (C), ANP (D), and β-MHC (E) in heart tissues. Means ± SEM, n = 5–8 mice per group, *p < 0.05 vs. L-V, *p < 0.05 vs. H-V.
TABLE 3 | Physical and biochemical characteristics of the study patients.

|                      | -ROSI | +ROSI | p Value |
|----------------------|-------|-------|---------|
| Patients (males/females) | 90 (41/49) | 30 (15/15) | 0.673   |
| Age (years) | 60.13 ± 10.58 | 63.07 ± 12.07 | 0.21    |
| Years with diabetes | 7.96 ± 5.24  | 7.67 ± 5.39  | 0.80    |
| Weight (kg) | 61.13 ± 11.16 | 62.38 ± 7.28  | 0.44    |
| BMI (kg/m²) | 23.47 ± 3.47 | 25.03 ± 2.35  | 0.088   |
| Fasting plasma glucose | 9.54 ± 3.41 | 8.90 ± 2.89 | 0.65    |
| HbA1c (%) | 8.92 ± 2.44 | 8.04 ± 1.56  | 0.11    |
| Total cholesterol (mmol/L) | 4.27 ± 1.26 | 4.57 ± 0.66  | 0.28    |
| TG (mmol/L) | 2.05 ± 2.94 | 2.05 ± 1.10  | 0.75    |
| LDL-cholesterol (mmol/L) | 1.20 ± 0.36 | 1.19 ± 0.35  | 0.95    |
| HDL-cholesterol (mmol/L) | 2.61 ± 0.96 | 2.83 ± 0.79  | 0.30    |
| Systolic blood pressure (mmHg) | 133.21 ± 19.30 | 135.58 ± 19.61 | 0.58    |
| Diastolic blood pressure (mmHg) | 78.64 ± 10.93 | 73.65 ± 18.24 | 0.098   |
| Hematocrit value (%) | 39.04 ± 4.80 | 39.02 ± 5.98  | 0.99    |
| ALP (μmol/L) | 79.45 ± 24.13 | 66.5 ± 17.43  | 0.008   |
| BUN (mmol/L) | 5.88 ± 2.20 | 5.95 ± 1.58  | 0.23    |
| Scr (μmol/L) | 66.72 ± 28.36 | 71.37 ± 20.47 | 0.03    |

Means ± SD. ‑ROSI represents patients without treatment with rosiglitazone, and +ROSI represents patients treated with rosiglitazone.

et al., 2015). Other partial agonists, telmisartan, FMOC-L-Leu and PA-082, for instance, also showed a decrease in side effects, such as adipogenesis and weight gain, possibly due to differences in recruiting different coactivators (Burgermeister et al., 2006; Liu et al., 2015). Other partial agonists, telmisartan, FMOC-L-Leu ± Means ± SD. ‑ROSI represents patients without treatment with rosiglitazone, and +ROSI represents patients treated with rosiglitazone. expected, by using echocardiographical examination, both rosiglitazone and CMHX008 treatment could improve myocardial dysfunction induced by HFD, with similar improvement on ejection fraction and fractional shortening. However, the in vivo cardiomyocyte sizes were obviously increased and transcriptional levels of hypertrophy-related genes were up-regulated in HFD mice treated with rosiglitazone while CMHX008 treatment did not demonstrate hypertrophic phenotype. The similar results were also observed in PPARγ2-overexpressed cardiomyocytes in vitro, showing that mouse cardiac myocytes (MCM) overexpressing PPARγ2 displayed increased levels of hypertrophy-related genes (BNP and ANP) and increased cell size after treatment with rosiglitazone but CMHX008 did not show the same effect as rosiglitazone. Rosiglitazone potentially increased the risk of cardiac hypertrophy in obese mice, and more importantly, in our clinical observation, we also found that patients with rosiglitazone had signs for early myocardial damage and increased early volume load. Our clinical observation was generally in compliance with previous findings from a systematic review and meta-analysis, showing that the relative risk of heart failure with rosiglitazone increased compared with placebo controls (Diabetes Canada Clinical Practice Guidelines Expert Committee et al., 2013; Cheng et al., 2018). It should be noted that our present study was a retrospective analysis, and thereby a population based, large-scale cohort studies with a long-term follow-up are urgently needed. In addition, the results obtained from our current study and others collectively provide a need for novel insulin sensitizers with better effectiveness and safety. CMHX008 as a novel PPARγ partial agonist showed a comparative effect on heart function with better safety compared with rosiglitazone and may potentially be developed into a new drug to benefit T2DM with fewer cardiovascular events. In summary, our findings show that diabetic cardiomyopathy was associated with ectopic overexpression of PPARγ2. The full agonist rosiglitazone prevents cardiac dysfunction at the expense of compensatory hypertrophy, while the partial agonist CMHX008 shared a comparable protective effect without altering the structure of cardiomyocytes.

TABLE 4 | Echocardiographic parameters of the study patients.

|                      | -ROSI | +ROSI | p Value |
|----------------------|-------|-------|---------|
| LV EF (mmHg) | 63.74 ± 5.64 | 64.13 ± 3.79 | 0.73 |
| LV FS (%) | 35.31 ± 4.71 | 35.21 ± 2.62 | 0.92 |
| LV V (mL) | 10.08 ± 0.89 | 10.57 ± 0.93 | 0.011 (*) |
| LVDD (mm) | 47.42 ± 3.74 | 48 ± 2.65 | 0.445 |
| RVDD (mm) | 18.91 ± 2.02 | 19.13 ± 1.91 | 0.60 |
| RALD (mm) | 32.68 ± 3.06 | 32.97 ± 2.44 | 0.63 |
| LAD (mm) | 26.84 ± 5.06 | 32.97 ± 2.44 | <0.0001 (*) |
| SED (mm) | 31 ± 3.22 | 31.3 ± 4.41 | 0.567 |

Means ± SD. *(a)p < 0.05. *(b)p < 0.001 vs. -ROSI.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

XC, MM, JD, ZZ, and XX conceived and designed the study, contributed to the writing of the manuscript; XC, MM, JD, YH, HS, and YG conducted experiments, contributed to the acquisition and interpretation of data; JL, XT, CW, ZZ, and XX analysed and interpreted the data, and critically revised the manuscript. All authors read and approved the final manuscript.

REFERENCES

Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., et al. (2013). PPARγ Signaling and Metabolism: the Good, the Bad and the Future. Nat. Med. 19 (5), 557–566. doi:10.1038/nm.3159

Barbieri, M., Di Filippo, C., Esposito, A., Marfella, R., Rizzo, M. R., D’Amico, M., et al. (2012). Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-specific PPAR-γ Knockout (CM-PGKO) Mice. PloS One 7 (4), e35999. doi:10.1371/journal.pone.0035999

Brito, J., and Dvorak, Z. (2020). Natural and Synthetic Retinoid X Receptor Ligands and Their Role in Selected Nuclear Receptor Action. Biochimie 179, 157–168. doi:10.1016/j.biochi.2020.09.027

Burgermeister, E., Schnoebelen, A., Flament, A., Benz, J., Stihle, M., Geil, B., et al. (2006). A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-Gamma (PPARgamma) Recruits PPARgamma-Coactivator-1alpha, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling In Vitro. Mol. Endocrinol. 20 (4), 809–830. doi:10.1210/me.2005-0171

Chang, C. H., McNamara, L. A., Wu, M. S., Muisse, E. S., Tan, Y., Wood, H. B., et al. (2008). A Novel Selective Peroxisome Proliferator-Activator Receptor-Gamma Modulator-PPARgammaM5 Improves Insulin Sensitivity with Diminished Adverse Cardiovascular Effects. Eur. J. Pharmacol. 584 (1), 192–201. doi:10.1016/j.ejphar.2010.12.036

Cheng, D., Gao, H., and Li, W. (2018). Long-term Risk of Rosiglitazone on Cardiovascular Events - a Systematic Review and Meta-Analysis. Endokrynol. Pol. 69 (4), 381–394. doi:10.5603/EP.a2018.0036

Chigrupati, S., Dhanaraj, S. A., and Balakumar, P. (2015). A Step Ahead of PPAR Partial Agonist to PPAR PPARgamma Full Agonists: Therapeutic Perspectives in the Management of Diabetic Insulin Resistance. Eur. J. Pharmacol. 755, 50–57. doi:10.1016/j.ejphar.2015.02.043

Consoli, A., and Formoso, G. (2013). Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Metab. 15 (11), 967–977. doi:10.1111/diab.12101

Eldor, R., DeFronzo, R. A., and Abdul-Ghani, M. (2013). In Vivo actions of Peroxisome Proliferator-Activated Receptors: Glycemic Control, Insulin Sensitivity, and Insulin Secretion. Diabetes Care 36 (Suppl. 2), S162–S174. doi:10.2337/dc13-S103

Enrion, P. J., Evans, A. E., Sinnayah, P., Jobst, E. E., Tonelli-Lemos, L., Billes, S. K., et al. (2007). Diet-induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons. Cell Metab 5 (3), 181–194. doi:10.1016/j.cmet.2007.02.004

Goltsman, I., Khoury, E. E., Winaver, J., and Abassi, Z. (2016). Does Thiazolidinedione Therapy Exacerbate Fluid Retention in Congestive Heart Failure?. Pharmacol. Ther. 168, 75–97. doi:10.1016/j.pharmthera.2016.09.007

Hall, J. A., Ramachandran, D., Roh, H. C., DiSpiechio, J. R., Belchior, T., Zushin, P. H., et al. (2020). Obesity-Linked PPARγ S273 Phosphorylation Promotes Insulin Resistance through Growth Differentiation Factor 3. Cell Metab 32 (4), 665–e6. doi:10.1016/j.cmet.2020.08.016

Hiatt, W. R., Kaul, S., and Smith, R. J. (2013). The Cardiovascular Safety of Diabetes Drugs-Insights from the Rosiglitazone Experience. N. Engl. J. Med. 369 (14), 1285–1287. doi:10.1056/NEJMmp1309610

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., et al. (2009). Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a Multicentre, Randomised, Open-Label Trial. Lancet 373 (9681), 2125–2135. doi:10.1016/S0140-6736(09)60953-3

Hou, Y., Cao, X., Hu, X., Li, X., Shi, X., Wang, H., et al. (2018). CMHX008, a PPAR Partial Agonist, Enhances Insulin Sensitivity with Minor Influences on Bone Loss. Genes Dis. 5 (3), 290–299. doi:10.1016/j.gndis.2018.05.004

Diabetes Canada Clinical Practice Guidelines Expert Committee, Howlett, J. G., MacFadyen, J. C., and Liu, P. (2013). Treatment of Diabetes in People with Heart Failure. Can. J. Diabetes 37 (Suppl. 1), S126–S128. doi:10.1016/j.jcda.2013.01.036

Janani, C., and Ranjitha Kumari, B. D. (2015). PPAR Gamma Gene-Aa Review. Diabetes Metab. Syndr. 9 (1), 46–50. doi:10.1016/j.dsx.2014.09.015

Kolli, V., Stechschulte, L. A., Dowling, A. R., Rahman, S., Czernik, P. J., and Lecka-Czernik, B. (2014). Partial Agonist, Telmisartan, Maintains PPARγ Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass. PloS One 9 (5), e96323. doi:10.1371/journal.pone.0096323

Komajda, M., McMurray, J. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., et al. (2010). Heart Failure Events with Rosiglitazone in Type 2 Diabetes: Data from the RECORD Clinical Trial. Eur. Heart J. 31 (7), 824–831. doi:10.1093/eurheartj/ehp604

Krisnan, J., Suter, M., Windak, R., Krebs, T., Felley, A., Montessuit, C., et al. (2009). Activation of a HIF1alpha-PPARgamma axis Underlies the Integration of Glycolytic and Lipid Anabolic Pathways in Pathologic Cardiac Hypertrophy. Cell Metab 9 (6), 512–524. doi:10.1016/j.cmet.2009.05.005

Lebovitz, H. E. (2019). Thiazolidinediones: the Forgotten Diabetes Medications. Curr. Diab. Rep. 19 (12), 151. doi:10.1007/s11892-019-1270-y

Lecka-Czernik, B. (2010). Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. Curr. Osteoporos. Rep. 8 (4), 178–184. doi:10.1007/s11914-010-0027-y

Li, H., Li, M., Liu, P., Wang, Y., Zhang, H., Li, H., et al. (2016). Telmisartan Ameliorates Nephrapathy in Metabolic Syndrome by Reducing Leptin Release from Perirenal Adipose Tissue. Hypertension 68 (2), 478–490. doi:10.1161/HYPERTENSIONAHA.116.07008

FUNDING

This research was funded by the National Natural Science Foundation of China (82071734, 81871222 and 81570763) and the Fundamental Science and Advanced Technology Research of Chongqing (CSTC2019jcymxsmx0425).

ACKNOWLEDGMENTS

The authors are grateful to the Department of Ultrasound of the Third Military Medical University Affiliated Hospital for the excellent technical assistance on color Doppler ultrasonography assay.
Cao et al. PPARγ Ligands and Hypertrophic Cardiomyopathy

Luo, J., Wu, S., Liu, J., Li, Y., Yang, H., Kim, T., et al. (2010). Conditional PPAR Knockout from Cardiomyocytes of Adult Mice Impairs Myocardial Fatty Acid Utilization and Cardiac Function. *Am. J. Respir. Cell. Mol. Biol.* 43 (6), 1–72.

Ma, X., Wang, D., Zhao, W., and Xu, L. (2018). Deciphering the Roles of PPAR in Adipocytes via Dynamic Change of Transcription Complex. *Front. Endocrinol.* (Lausanne) 9, 473. doi: 10.3389/fendo.2018.00473

MacDonald, M. R., Petrie, M. C., Home, P. D., Komajda, M., Jones, N. P., Beck-Nielsen, H., et al. (2011). Incidence and Prevalence of Unrecognized Myocardial Infarction in People with Diabetes: a Substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study. *Diabetes Care* 34 (6), 1394–1396. doi: 10.2337/dc10-2398

Malone, J. L. and Hansen, B. C. (2019). Does Obesity Cause Type 2 Diabetes Mellitus (T2DM)? or Is it the Opposite? *Pediatr. Diabetes* 20 (1), 5–9. doi: 10.1111/pedi.12787

Ming, Y., Hu, X., Song, Y., Liu, Z., Li, J., Gao, R., et al. (2014). CMHX008, a Novel Peroxisome Proliferator-Activated Receptor Partial Agonist, Enhances Insulin Sensitivity In Vitro and In Vivo. *PLoS One* 9 (7), e102102. doi: 10.1371/journal.pone.0102102

Mousse, S. A., Shang, J., Eberhardt, J., Brust, R., Zheng, J., Griffin, P. R., et al. (2019). Structural Basis of Altered Potency and Efficacy Displayed by a Major In Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. *J. Med. Chem.* 62 (4), 2008–2023. doi: 10.1021/acs.jmedchem.8b01573

Nanjan, M. J., Mohammed, M., Prashantha Kumar, B. R., and Chandrasekar, M. J. N. (2018). Thiazolidinediones as Antidiabetic Agents: A Critical Review. *Bioorg. Chem.* 77, 548–567. doi: 10.1016/j.bioorg.2018.02.009

Ribeiro Filho, H. V., Guerra, J. V., Cagliari, R., Batista, F. A. H., Le Maire, A., Oliveira, P. S. L., et al. (2019). Exploring the Mechanism of PPARγ Phosphorylation Mediated by CDK5. *J. Struct. Biol.* 207 (3), 317–326. doi: 10.1016/j.jsb.2019.07.007

Rizos, C. V., Kei, A., and Eliasf, M. S. (2016). The Current Role of Thiazolidinediones in Diabetes Management. *Arch. Toxicol.* 90 (8), 1861–1881. doi: 10.1007/s00204-016-1737-4

Ryan, K. K., Li, B., Grayson, B. E., Matter, E. K., Woods, S. C., and Seeley, R. J. (2011). A Role for central Nervous System PPAR-γ in the Regulation of Energy Balance. *Nat. Med.* 17 (5), 623–626. doi: 10.1038/nm.2349

Saltiel, A. R. (2016). New Therapeutic Approaches for the Treatment of Obesity. *Sci. Transl. Med.* 8 (323), 323rv2. doi: 10.1126/scitranslmed.aad1811

Semple, R. K., Chatterjee, V. K., and O’Rahilly, S. (2006). PPAR Gamma and Human Metabolic Disease. *J. Clin. Invest.* 116 (3), 581–589. doi: 10.1172/JCI30335

Son, N. H., Park, T. S., Yamashita, H., Yokoyama, M., Huggins, L. A., Okajima, K., et al. (2007). Cardiomyocyte Expression of PPARgamma Leads to Cardiac Dysfunction in Mice. *J. Clin. Invest.* 117 (10), 2791–2801. doi: 10.1172/JCI30335

Stechschulte, L. A., Czernik, P. J., Rotter, Z. C., Tausif, F. N., Corzo, C. A., Marciano, D. P., et al. (2016). PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption. *EBioMedicine* 10, 174–184. doi: 10.1016/j.ebiom.2016.06.040

Thornton, B., and Basu, C. (2015). Rapid and Simple Method of qPCR Primer Design. *Methods Mol. Biol.* 1275, 173–179. doi: 10.1007/978-1-4939-2365-6_13

Wang, L., Wallenberger, B., Fierswegen-Wenzig, E. M., Blunder, M., Liu, X., Malaliner, C., et al. (2014). Natural Product Agonists of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ): a Review. *Biochem. Pharmacol.* 92 (1), 73–89. doi: 10.1016/j.bcp.2014.07.018

Yang, H. L., Kim, W. S., Kim, D. H., and Kang, J. S. (2013). Histopathological Evaluation of Heart Toxicity of a Novel Selective PPAR-γ Agonists CKD-501 in Db/db Mice. *Biomed. Ther.* (Seoul) 21 (1), 84–88. doi: 10.4062/biomolther.2012.101

Yasmin, S., Capone, F., Laghezza, A., Piaz, F. D., Loiodice, F., Vijayan, V., et al. (2017). Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and Their Antidiabetic Effects on Type 2 Diabetes. *Sci. Rep.* 7 (1), 14453. doi: 10.1038/s41598-017-14776-0

Yki-Järvinen, H. (2004). Thiazolidinediones. *N. Engl. J. Med.* 351 (11), 1106–1118. doi: 10.1056/NEJMra041001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Cao, Mao, Diao, Hou, Su, Gan, Li, Tong, Wu, Zuo and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.